

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award

written by Raj Shah | April 2, 2024

April 2, 2024 ([Source](#)) – Coeptis Therapeutics Holdings, Inc. (Nasdaq: [COEP](#)) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, is pleased to acknowledge and congratulate Professor Alexander Deiters, on receiving the University of Pittsburgh’s 2024 Chancellor’s Distinguished Research Award. This prestigious award honors outstanding individuals whose scholarly commitments and contributions to research have significantly advanced their respective fields. Deiters co-developed a CAR T cell therapy platform called “SNAP-CAR” that is based on covalent modification of a universal receptor with adaptor molecules that target these T cells to tumors.

Alexander Deiters, chemistry professor in the Kenneth P. Dietrich School of Arts and Sciences, was honored for his innovation and interdisciplinary research at the interface of chemistry and biology, which aims to discover new therapeutic approaches and improve human health. For example, by discovering inhibitors of the microRNA pathway and of enzymes involved in phase II metabolism. Deiters’ peers described him as “one of the

most productive research contributors in the field” whose research program “shows both breadth and depth.”

“We commend Deiters for his outstanding dedication and invaluable contributions to the development of SNAP-CAR T technology,” said Dave Mehalick, President and CEO of Coeptis Therapeutics. “We are excited to help advance the groundbreaking SNAP-CAR technology as potential therapies for a range of conditions within the fields of oncology and autoimmune disorders, where significant treatment gaps persist. Given its vast potential, these technologies have the opportunity to revolutionize the treatment paradigm across multiple healthcare sectors.”

The Company recently expanded its exclusive license agreement with the University of Pittsburgh to include the SNAP-CAR technology platform in natural killer (NK) cells and autoimmune indications. Recent research suggests that CD19-targeting chimeric antigen receptor CAR T cells, which have proven to be highly efficient in B cell malignancies, can also target autoreactive B cells that trigger autoimmune diseases.

About Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively “Coeptis”), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis’ product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from

the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer and infectious diseases. The Company is headquartered in Wexford, PA. For more information on Coeptis visit <https://coeptistx.com/>.

Cautionary Note Regarding Forward-Looking Statements

This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the risk that the integration of the Deverra licensed assets will disrupt current plans and operations of the

Company; (3) the inability to recognize the anticipated benefits of the newly-licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (4) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (5) costs related to integrating the newly-licensed Deverra assets and pursuing the contemplated asset development paths; (6) changes in applicable laws or regulations; (7) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (8) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.